Larimar Therapeutics Retained Earnings History
| LRMR Stock | USD 4.13 0.04 0.98% |
Retained Earnings | First Reported 2014-06-30 | Previous Quarter -372.33 million | Current Value -434.83 million | Quarterly Volatility 109.03 million |
Macro event markers
Latest Larimar Therapeutics Retained Earnings Growth Pattern
| Retained Earnings | 10 Years Trend |
|
Retained Earnings |
| Timeline |
Retained Earnings Trend Statistics
Larimar Therapeutics reports Retained Earnings with a coefficient of variation of 73.4% over 14 periods, reflecting elevated dispersion relative to the mean. R-squared at 0.41 is consistent with a moderate linear trend with partial explanatory power.| Arithmetic Mean | -179,935,732 | |
| Coefficient Of Variation | -73.42 (interpretation is limited given the negative mean) | |
| Mean Deviation | 108,723,920 | |
| Median | -151,605,000 | |
| Standard Deviation | 132,114,829 | |
| Sample Variance | 17454.3T | |
| Range | 411.7M | |
| R-Value | -0.64 | |
| Mean Square Error | 11076.7T | |
| R-Squared | 0.41 | |
| Significance | 0.01 | |
| Slope | -16,650,827 | |
| Total Sum of Squares | 279269.2T |
Larimar Therapeutics Retained Earnings History
Larimar Therapeutics' Retained Earnings record extends from 2013 to 2026, covering 14 observations from -68.91 million to -413.09 million.Correlation of Retained Earnings With Other Accounts
Linear correlations between Retained Earnings and other accounts within Larimar Therapeutics' reporting history are shown below. Strong correlations may reflect underlying operational relationships or scaling effects across related metrics.Click cells to compare fundamentals
Related Fundamentals
| Last Reported | End Of Year Estimate | ||
| Retained Earnings Total Equity | $-136.44 million | $-143.27 million | |
| Depreciation And Amortization | $350,000 | $205,385 | |
| Gross Profit | $-350,000 | $-332,500 | |
| Other Operating Expenses | $172.5 million | $181.12 million | |
| Operating Income | $-172.5 million | $-163.87 million | |
| EBIT | $-172.85 million | $-164.2 million |
Methodology, Assumptions & Data Sources
A longitudinal view of Larimar Therapeutics's Retained Earnings is provided for trend analysis. Sequential period comparisons surface inflection points that rolling averages can obscure. As a technology-driven company, Larimar Therapeutics' Retained Earnings reflects ownership capital supporting the operating base.
Larimar Therapeutics inputs come from periodic company reporting and market reference feeds and are mapped into a consistent reporting framework. Analyst inputs may be included when coverage is available. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board